MedTrace Logo

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

NCT07608003 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-05-27

No results posted yet for this study

Summary

A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.

Conditions

  • Gliomas Harboring IDH1 and/or IDH2 Mutations
  • Glioma Glioblastoma Multiforme
  • Glioma of Brainstem
  • Glioma, Diffuse Midline, H3K27M-mutant
  • Glioma : Oligodendroglioma or Astrocytoma
  • Gliomas

Sponsors & Collaborators

  • Xiangya Hospital of Central South University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-10
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07608003 on ClinicalTrials.gov